Key points from article :
Longevity Vision Fund is excited to announce its investment into Sigilon Therapeutics.
It joined the Series B financing total of $80.3 million led by Flagship Pioneering.
The financing round brings Sigilon’s total funding to more than $195 million.
The funding will support the first-in-human clinical trial of Sigilon.
For novel encapsulated cell therapy for hemophilia A.
Sigilon has a global collaboration with Eli Lilly.
To develop encapsulated cell therapies for potential treatment of type 1 diabetes.
Sigilon’s technology has a great potential to liberate patients from treatment challenges.
Its lead investigational therapy for hemophilia A is called SIG-001.
It has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).
Expected to initiate a first-in-human clinical trial of SIG-001 in the first half of 2020.